New Value Capital's Series A investment project, Qiyu Biologics, announced that its self-developed Q-1801 project obtained the domestic CDE clinical trial approval notice on January 2023, 1, after the project had previously obtained clinical approval from the US FDA. Developed by Qiyu Biologics using its antibody engineering technology platform, Q-11 is the world's first bispecific antibody targeting both SIRPα and PD-L1801. Q-1 is also the second clinical application project of Qiyu Biologics. So far, Qiyu Biotech has obtained four Sino-US IND approvals.

About the Q-1801

SIRPα is mainly expressed in myeloid cells such as macrophages, dendritic cells (DCs), tumor-associated macrophages (TAMs), and myelin-derived suppressor cells (MDSCs). PD-L1 is mainly expressed in myeloid cells such as tumor cells and DCs. On the one hand, Q-1801 blocks the binding of SIRPα and CD47 through SIRPα antibodies, eliminating its inhibitory effect without producing hemotoxicity. On the other hand, PD-L1 antibody blocks PD-L1 inhibitory signal and activates the specific killing effect of T cells on tumors. Q-1801 activates both natural immunity and adaptive immune response, which can enhance the anti-tumor immunity of the body by enhancing DC antigen presentation function, enhancing the phagocytosis and inflammatory properties of macrophages in the tumor microenvironment, and differentiating MDSCs into effector states. Further, for tumors expressing PD-L1, Q-1801 can target and activate the above pathway and target the tumor, and it is expected that Q-1801 can benefit patients in clinical trials.

About Healing Creatures

Qiyu Biotech is an international company focusing on the research and development of innovative macromolecular biologics, committed to solving the urgent and unmet clinical needs of refractory cancer, autoimmunity and so on. Founded by senior scientists in related fields, the company has built proprietary technologies for the development of biological macromolecules, including innovative platforms for bispecific and tertiary antibodies. Qiyu Biotech completed a Series B financing of nearly RMB 2021 million at the end of 2.
 

Qiyu Biologics is looking for partners around the world to explore new therapies with unmet clinical needs. Previously, relying on its own technology platform, Qiyu Biotech has reached a series of cooperation with well-known companies in the industry, including Bangyao Biotechnology, Hengrui Pharmaceutical, and Puri Benchmark.